Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Moclobemide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 1/20 | 1.00 |
| ▸ | CD274 | Q9NZQ7 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | MAOB | P27338 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.72 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | CNR1 | P21554 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Moclobemide SCHEMBL3408310 | 1.00 | CD274 (1.00) | CD274ALDH1A1HTR1AMAOAMAOB | |
| Moclobemide SCHEMBL11475483 | 0.99 | CD274 (0.97) | CD274ALDH1A1HTR1AMAOAMAOB | |
| Eprobemide SCHEMBL570896 | 0.92 | ALDH1A1 (0.85) | CD274ALDH1A1HTR1AMAOAMAOB | |
| Eprobemide SCHEMBL10495496 | 0.91 | ALDH1A1 (0.82) | CD274ALDH1A1HTR1AMAOAMAOB | |
| SCHEMBL10723708 | 0.90 | ALDH1A1 (0.85) | CD274ALDH1A1HTR1AMAOAMAOB | |
| SCHEMBL4488493 | 0.87 | CD274 (0.77) | CD274ALDH1A1HTR1AMAOAMAOB | |
| SCHEMBL6569882 | 0.87 | CD274 (0.77) | CD274ALDH1A1HTR1AMAOAMAOB | |
| SCHEMBL2251460 | 0.86 | CD274 (0.76) | CD274ALDH1A1HTR1AMAOAMAOB | |
| SCHEMBL6034019 | 0.86 | TSHR (0.85) | CD274ALDH1A1HTR1AMAOAMAOB | |
| SCHEMBL2615239 | 0.86 | CD274 (0.92) | CD274ALDH1A1HTR1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 14676 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727545-A2 | COMBINATION TREATMENTS FOR DEPRESSION AND OTHER DISORDERS | Neurawell Therapeutics (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4712996-A1 | HIP/PAP PROTEIN OR A DERIVATIVE THEREOF FOR TREATING A COGNITIVE DISORDER ASSOCIATED WITH ANXIETY DISORDER | THE HEALTHY AGING COMPANY (FR) | 2026-03-25 | — | — | EP | claimed |
| US-12544385-B2 | Combination drug therapies for CNS disorders | JAVED MOHAMMAD (US) | 2026-02-10 | — | — | US | claimed |
| US-20260034106-A1 | Macrocyclic ligands for FK506-binding proteins for treatment of diseases with improved characteristics | UNIV DARMSTADT TECH (DE) | 2026-02-05 | — | — | US | claimed |
| US-20260034065-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2026-02-05 | — | — | US | claimed |
| EP-4686495-A1 | MACROCYCLIC LIGANDS FOR FK506-BINDING PROTEINS FOR TREATMENT OF DISEASES WITH IMPROVED CHARACTERISTICS | Technische Universität Darmstadt (DE) | 2026-02-04 | — | — | EP | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| US-20260001942-A1 | TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO | H LUNDBECK AS (DK) | 2026-01-01 | — | — | US | claimed |
| WO-2025262247-A1 | TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO | H. LUNDBECK A/S (DK) | 2025-12-26 | — | — | WO | claimed |
| US-12472146-B2 | Extended release pharmaceutical formulation | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2025-11-18 | — | — | US | claimed |
| US-5371082-A | Treatment of anxiety disorders | VERSIANI MARCIO (BR) | 1994-12-06 | — | — | US | claimed |
| EP-0326023-B1 | Benzamide against cognitive disorders | HOFFMANN LA ROCHE (CH) | 1994-10-26 | — | — | EP | claimed |
| CN-1094040-A | The synthetic method of moclobemide | SCIENCE AND TECHNOLOGY DEV DEP (CN) | 1994-10-26 | — | — | CN | claimed |
| EP-0440704-A1 | COMPOSITIONS FOR TREATING TOBACCO WITHDRAWEL SYMPTOMS. | MASSACHUSETTS INST TECHNOLOGY (US) | 1991-08-14 | — | — | EP | claimed |
| EP-0386117-A1 | TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1990-09-12 | — | — | EP | claimed |
| WO-1990004387-A2 | COMPOSITIONS FOR TREATING TOBACCO WITHDRAWAL SYMPTOMS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1990-05-03 | — | — | WO | claimed |
| US-4906626-A | Method of use for treatment or prevention of cognitive disorders | HOFFMAN-LA ROCHE INC. (US) | 1990-03-06 | — | — | US | claimed |
| EP-0326023-A2 | Benzamide against cognitive disorders | F. HOFFMANN-LA ROCHE AG (CH) | 1989-08-02 | — | — | EP | claimed |
| WO-1989003692-A1 | TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1989-05-05 | — | — | WO | claimed |
| US-4210754-A | ANTIDEPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1980-07-01 | — | — | US | claimed |